J&J Gets EU Complaint With Novartis on Pay-for-Delay Deal

Johnson & Johnson and Novartis AG were sent antitrust objections by European Union regulators over a pay-for-delay deal that may have hampered the sale of generic versions of pain killer fentanyl in the Netherlands.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.